Arbutus Biopharma Corp (NASDAQ: ABUS) stock jumped 0.54% on Friday to $1.86 against a previous-day closing price of $1.85. With 0.81 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.64 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.8700 whereas the lowest price it dropped to was $1.7700. The 52-week range on ABUS shows that it touched its highest point at $3.14 and its lowest point at $1.69 during that stretch. It currently has a 1-year price target of $4.60. Beta for the stock currently stands at 1.87.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ABUS was up-trending over the past week, with a rise of 5.08%, but this was up by 6.29% over a month. Three-month performance dropped to -9.27% while six-month performance fell -27.63%. The stock lost -31.11% in the past year, while it has lost -20.17% so far this year. A look at the trailing 12-month EPS for ABUS yields -0.47 with Next year EPS estimates of -0.44. For the next quarter, that number is -0.12. This implies an EPS growth rate of 3.04% for this year and 1.79% for next year.
Float and Shares Shorts:
At present, 157.46 million ABUS shares are outstanding with a float of 125.84 million shares on hand for trading. On Oct 30, 2023, short shares totaled 6.31 million, which was 3.76% higher than short shares on Sep 28, 2023. In addition to Mr. William H. Collier as the firm’s President, CEO & Director, Mr. Michael J. McElhaugh serves as its Co-Founder, COO & Chief Business Officer.
Through their ownership of 37.96% of ABUS’s outstanding shares, institutional investors have minority control over the company.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ABUS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ABUS analysts setting a high price target of $6.00 and a low target of $4.00, the average target price over the next 12 months is $4.60. Based on these targets, ABUS could surge 222.58% to reach the target high and rise by 115.05% to reach the target low. Reaching the average price target will result in a growth of 147.31% from current levels.
Summary of Insider Activity:
Insiders traded ABUS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 1,062,200 while 0 shares were sold.